This study is a 2-arm, double blinded, randomised clinical trial where 40 participants will be assigned 1:1 to insulin treatment alone (control) or insulin treatment and tirzepatide treatment for 32 weeks. The primary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks adjunctive to insulin treatment can reduce body weight in patients with T1D and overweight or obesity when compared to insulin treatment alone. The secondary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks can improve glycaemic control (measured by hbA1c), improve time in range, reduce insulin requirements, and reduce the severity of comorbidities in people with obesity and T1D. This trial includes a 6 month follow-up period.

开始日期2026-12-01

申办/合作机构

Royal North Shore Hospital

NCT07179120

/ Not yet recruiting临床2期IIT

Male Fertility Preservation: Efficacy Evaluation of GLP-1Receptor Agonist Therapy for Infertility in Obese Males - A Multicenter Clinical Randomized Controlled Trial

Why is this study being done? Obesity can harm men's fertility by lowering sperm quality and hormone levels, making it harder to have children. Weight loss through diet and exercise helps, but it's often hard to stick with. New medicines called GLP-1 receptor agonists, like semaglutide (Ozempic) and tirzepatide (Mounjaro), help people lose weight and improve health. Early studies suggest these drugs might also boost sperm health in obese men, but more proof is needed. This study tests if these drugs can safely improve fertility in obese men who are having trouble conceiving.
What will happen in this study?
This is a 48-week study at several hospitals in China. About 180 men will be randomly assigned to one of three groups:
Group 1: Standard lifestyle changes, like a healthy diet and exercise, guided by experts.
Group 2: Weekly injections of semaglutide, starting low and increasing as tolerated.
Group 3: Weekly injections of tirzepatide, starting low and increasing as tolerated.
All men will have regular check-ups, including blood tests, semen analysis, and weight measurements. We will track sperm quality, hormone levels, weight loss, and whether their partners get pregnant naturally. The study includes an 8-week adjustment period, 24 weeks of treatment, and 16 weeks of follow-up.
Who can join this study? Men aged 20-45 who are married, obese (BMI 28 or higher or waist size 90 cm or more), and have been trying to have a baby for at least a year without success due to low sperm count or poor sperm movement. Their female partners must be under 40 and have no major fertility issues. Men must be willing to attend visits and provide samples. People with serious health problems, recent use of similar drugs, or other causes of infertility (like genetic issues) cannot join.
How long will this study last? The full study lasts 48 weeks (about 11 months), with visits every 4-8 weeks, plus monthly phone check-ins for pregnancy updates.
What are the possible benefits and risks? Benefits: If the drugs work, men may lose weight, improve sperm quality, and have a better chance of their partners getting pregnant naturally. They might also feel healthier overall. Risks: Common side effects include nausea, vomiting, or diarrhea from the drugs, which usually improve over time. Rare risks include pancreas inflammation or gallbladder issues. Lifestyle changes might cause minor injuries from exercise. All side effects will be monitored closely, and participants can quit anytime. Insurance covers any study-related harm.

开始日期2026-05-01

申办/合作机构

温州医科大学附属第一医院

NCT05933499

/ Not yet recruiting临床2期IIT

Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

In adults with obesity seeking treatment, weight loss would ideally be composed almost exclusively of fat mass. However, loss of muscle mass and bone are unintentional consequences of weight loss, which may have negative effects on health by lessening improvements in glucose and insulin levels, reducing resting metabolic rate, and increasing the risk of falls and fractures. Data in animals and humans suggest that bimagrumab, an investigational new drug for obesity that inhibits the activin type II receptor (ActRII) inhibitor, may help maximize loss of fat mass while maintaining muscle mass when used in combination with a glucagon-like peptide 1 receptor agonist (GLP-1 RA). The investigators hypothesize that in a randomized, placebo-controlled trial of 63 adults with obesity randomized to tirzepatide (GLP-1/GIP RA) + bimagrumab, tirzepatide alone, or bimagrumab alone, the combination of tirzepatide + bimagrumab will result in improvements in muscle, fat, and bone compared to tirzepatide alone or bimagrumab alone when given in addition to a lifestyle intervention for weight loss over 52 weeks.

开始日期2025-12-15

申办/合作机构

The Schwartz Center for Compassionate Healthcare

100 项与替尔泊肽相关的临床结果

登录后查看更多信息

100 项与替尔泊肽相关的转化医学

登录后查看更多信息

100 项与替尔泊肽相关的专利（医药）

登录后查看更多信息

1,383

项与替尔泊肽相关的文献（医药）

2026-02-01·TISSUE & CELL

Tirzepatide enhances liver structural integrity by promoting mitochondrial dynamics and mitophagy via PINK1/PRKN and SIRT3/NRF2 pathways in an obese-diabetic-menopausal mouse model

Article

作者: Marinho, Thatiany S ; Aguila, Marcia B ; Marcondes-de-Castro, Ilitch A ; Mandarim-de-Lacerda, Carlos A

The effects on hepatic mitochondrial structure, mitophagy, and cellular homeostasis were investigated when treated with Tirzepatide (Tzp), a dual GIP/GLP-1 receptor agonist, in a mouse model combining obesity, type 2 diabetes, and menopause-conditions that collectively exacerbate metabolic dysfunction-associated steatotic liver disease (MASLD). Female C57BL/6 mice were fed either a control or high-fat, high-sucrose diet for 12 weeks, and half underwent bilateral ovariectomy to simulate menopause. Tzp was administered daily for four weeks. Liver tissue was evaluated for ultrastructural alterations, gene expression, and protein profiles. Untreated obese-diabetic and obese-diabetic-ovariectomized mice exhibited hepatocellular fat accumulation, mitochondrial swelling, and disorganized cristae, indicative of metabolic and oxidative stress. In contrast, Tzp-treated mice displayed preserved hepatic architecture and intact mitochondrial morphology. Tzp significantly downregulated autophagy genes (Ulk3, Atg5, Atg7) and key mitophagy regulators (PINK1, PRKN), reestablishing mitochondrial balance, primarily through the modulation of mitophagy and enhanced organelle stability. Simultaneously, it upregulated mitochondrial biogenesis markers (Ppargc1a, Tfam), antioxidant enzymes (SOD2, GR, GPX, CAT), and redox modulators (Sirt3, Nrf2), while normalizing oxidative stress-related genes (Nos1, Nox1). Tzp also mitigated endoplasmic reticulum (ER) stress by downregulating Atf4, Ddit3, and Gadd45 and rebalanced mitochondrial dynamics through the suppression of fission markers (Dnml1, Fis1) and the restoration of fusion mediators (Mfn1, Mfn2). Three-way ANOVA confirmed Tzp's broad regulatory effects on hepatic gene expression, while principal component analysis revealed clear transcriptional separation between treated and untreated groups. In conclusion, these findings demonstrate that Tzp preserves liver ultrastructure and restores mitochondrial dynamics, supporting its therapeutic potential in MASLD and hormone-related metabolic disorders.

2026-01-01·Methods in molecular biology (Clifton, N.J.)

Assessing the Role of PPKs in Phosphorylating Phytochrome A Using the Protoplast Transient Expression System

Article

作者: Feng, Ziyi ; Li, Jigang

Phytochrome A (phyA) is the far-red (FR) light photoreceptor in plants, and its phosphorylation status plays a critical role in modulating its protein activity and function. The protoplast transient expression system has become an increasingly efficient approach for analyzing promoter activities, protein subcellular localization, protein-protein interactions, etc. Recently, we employed the protoplast transient expression system to assess the role of the protein kinases PHOTOREGULATORY PROTEIN KINASES (PPKs) in phosphorylating phyA. TANDEM ZINC-FINGER/PLUS3 (TZP), a phyA-interacting protein previously shown to mediate phyA phosphorylation in vivo, was coexpressed with phyA and PPKs in Arabidopsis protoplasts. After the treatment with FR light, we observed that PPKs can directly phosphorylate phyA and that TZP enhances PPKs-mediated phosphorylation of phyA in Arabidopsis protoplasts. In this chapter, we will describe the detailed experimental procedures and the key points for implementing this system. This system may also be feasible for validating the relationship between other kinases and their potential substrates.

2025-12-31·Journal of Pharmaceutical Policy and Practice

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

Article

作者: Saseen, Joseph J. ; Dardouri, Mouna ; Nair, Kavita V. ; Moore, Gina D. ; DiStefano, Michael J.

Background:

High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristics, and advertising content of direct-to-consumer providers of compounded glucagon-like peptide-1 products for weight loss in Colorado.

Methods:

We conducted a cross-sectional study of websites advertising compounded glucagon-like peptide-1 products for weight loss in Colorado. Websites were identified using Google searches focused on census-defined statistical areas. Searches were conducted between March 21 and April 12, 2024. Data collected from websites included physical addresses, business type, highest reported staff credential, advertised glucagon-like peptide-1 products, whether businesses referred to Food and Drug Administration approval when describing products, and whether businesses referred to products as 'generic'.

Results:

We identified 93 business websites advertising compounded glucagon-like peptide-1 products for weight loss corresponding to 188 physical locations throughout Colorado. Most businesses were self-categorized as medical/health spas (33/93) or weight loss services (26/93). Advertised products included semaglutide (92/93), tirzepatide (40/93), liraglutide (2/93), and retatrutide (1/93). Advertised combination products included B vitamins (8/93), levocarnitine (1/93), mannitol (1/93), BPC-157 (1/93), and glycine (1/93). Seven websites advertised oral formulations. Additionally, 41/93 websites referred to Food and Drug Administration approval in their descriptions of compounded products and 5/93 referred to products as 'generic'.

Conclusion:

This study identified several instances of unapproved glucagon-like peptide-1 products being compounded and advertised in Colorado. Additionally, 1 product was advertised as compounded with BPC-157, a substance determined by the Food and Drug Administration to be unsafe for compounding. This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products. Regulatory action is needed to ensure the benefits of compounded GLP-1 products outweigh the risks.

3,552

项与替尔泊肽相关的新闻（医药）

2025-10-29

·PRNewswire

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025

Poster Presentation on VENTURE Study Results Evaluating Impact of VK2735 on Prediabetes and Cardiometabolic Status Additional Poster Presentations Scheduled for American Heart Association Scientific Sessions 2025 SAN DIEGO, Oct. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company's VK2735 obesity program will be the focus of two poster presentations at ObesityWeek® 2025, the annual meeting of The Obesity Society. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors being developed for the potential treatment of various metabolic disorders. Viking is evaluating both subcutaneous and oral formulations of VK2735 in clinical trials. ObesityWeek 2025 is being held November 4-7, 2025, in Atlanta, Georgia. One ObesityWeek presentation will report results of an exploratory analysis from the company's Phase 2 VENTURE clinical trial, which evaluated 13 weeks of weekly treatment with a subcutaneous formulation of VK2735 in obese subjects. The exploratory analysis evaluated the impact of VK2735 treatment on the prevalence of prediabetes and metabolic syndrome over the 13-week study. A second presentation will highlight the design of the company's ongoing Phase 3 VANQUISH-1 study of subcutaneous VK2735 in patients with obesity or who are overweight with at least one weight-related co-morbid condition. Viking will also make two presentations at the upcoming American Heart Association (AHA) Scientific Sessions 2025, which is being held November 7-10, 2025, in New Orleans, Louisiana. One presentation will share the design of the company's ongoing Phase 3 VANQUISH-2 study of subcutaneous VK2735 in Type 2 diabetes patients with obesity or who are overweight. The second poster will share results of an analysis of the prevalence of cardiometabolic conditions across different body mass index categories. Details of the ObesityWeek and AHA presentations are as follows: ObesityWeek 2025 Poster Presentation: Title: VANQUISH-1 Study Design: Phase 3 Trial of Subcutaneous VK2735 in Adults with Overweight or Obesity Presenting Author: Karen Modesto, M.D., Vice President, Clinical Development, Viking Therapeutics Date/Time: Wednesday, November 5, 2025, 2:30 – 3:30 p.m. Eastern Time Poster Presentation: Title: Impact of Subcutaneous VK2735 on Weight, Prediabetes, and Cardiometabolic Status: The VENTURE Study Presenting Author: Harold Bays, MD, MFOMA, FTOS, FACC, FNLA, FASPC, DABOM, Louisville Metabolic and Atherosclerosis Research Center Date/Time: Thursday, November 6, 2025, 2:30 – 3:30 p.m. Eastern Time AHA Scientific Sessions 2025 Presentation ID: Sa2063 Title: VANQUISH-2: Phase 3, Randomized, Double-blind, Placebo-controlled, Trial of weekly subcutaneous administration of VK2735 in Obese or Overweight Adults with Type 2 Diabetes Presenting Author: Karen Modesto, M.D., Vice President, Clinical Development, Viking Therapeutics Date/Time: Saturday, November 8, 2025, 10:30 – 11:30 a.m. Central Time Presentation ID: Sa2052 Title: Prevalence of Cardiometabolic Conditions Across Body Mass Index Categories: The Distinct Burden of Severe (class III) Obesity Presenting Author: Saif Rathore, M.D., Ph.D., Sandbar Life Sciences Date/Time: Saturday, November 8, 2025, 2:30 – 3:30 p.m. Central Time About GLP-1 and Dual GLP-1/GIP Agonists Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both. Semaglutide is a GLP-1 receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Ozempic®, Rybelsus®, and Wegovy®. More recently, research efforts have explored the potential co-activation of the glucose-dependent insulinotropic peptide (GIP) receptor as a means of enhancing the therapeutic benefits of GLP-1 receptor activation. Tirzepatide is a dual GLP-1/GIP receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Mounjaro® and Zepbound®. About Viking Therapeutics, Inc. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 1 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo. For more information about Viking Therapeutics, please visit . SOURCE Viking Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期临床结果临床1期上市批准临床3期

2025-10-29

·QQ浏览器

CGC 2025丨双引擎驱动，减重更护肝：Survodutide新数据发布

编者按：代谢相关脂肪性肝病（MAFLD）是全球高发的慢性肝病，而代谢相关脂肪性肝炎（MASH）作为MAFLD的严重类型，以肝细胞损伤、小叶炎症及肝纤维化为核心特征[1, 2]，不仅显著增加肝硬化、肝癌风险，且全球患病率持续上升[3]，而现有治疗手段有限，难以满足临床需求。在这一背景下，MASH的全球药物研发管线日趋丰富，涌现出包括基于胰高血糖素样肽-1（GLP-1）的单/多靶点药物、甲状腺激素受体β（THR-β）在内的多类在研新药。其中，胰高血糖素受体（GCGR）/GLP-1受体（GLP-1R）双靶点药物因兼具代谢与肝脏调节而受到广泛关注。在近期召开的中华医学会第二十五次消化系病学术会议（CGC 2025）上，GCGR/GLP-1R双激动剂Survodutide公布了一系列研究成果，展现出MASH治疗的潜力。为及时传递前沿动态、助力临床实践与科研探索，本刊特对Survodutide的相关研究进展予以整理。作为MASH治疗领域的潜力创新药物，Survodutide不断积累的积极新证，为未来突破MASH治疗瓶颈、改善患者长期预后带来新的可能。机制解码 Survodutide如何直击MASH核心Survodutide作为创新GCGR/GLP-1R双激动剂，通过协同激活两种受体，在机制上区别于单一GLP-1R激动剂[4, 5]。具体表现为，GLP-1R可促进葡萄糖依赖性胰岛素分泌、延缓胃排空、抑制食欲，通过改善糖代谢与减少食物摄入间接改善肝脏代谢；GCGR可直接促进肝细胞内脂肪酸氧化、减少肝脏脂肪合成、促进肝脏脂肪分解；间接促进脂肪组织的脂肪分解；直接促进糖原分解、糖异生（图1）。 GCGR/GLP-1R双激动剂可直接靶向肝脏，通过GLP-1R激动作用（减少能量摄入）与GCGR激动作用（增加能量消耗）相结合，为改善肥胖和MASH患者的代谢健康提供了一种新的治疗策略。图1. GCGR/GLP-1R的双重激动作用Survodutide是由内源性激素胰高血糖素（GCG）与GLP-1优化得到的29个氨基酸肽段，通过两项结构优化设计延长半衰期并确保药效[6]：一是引入可抵抗二肽基肽酶-4（DPP-4）水解的合成氨基酸，同时添加增强溶解度与稳定性的氨基酸；二是通过含C18二酸的甘氨酸-丝氨酸连接子介导白蛋白结合，显著降低肾脏清除率。研究数据新探 Survodutide在MASH治疗中的潜力本次会上，Survodutide有多项针对性研究同步释放亮眼成果。这些研究具体涵盖减重之外的肝脏直接效应解析、无创生物标志物的持续改善追踪以及体外肝球体模型的机制验证，多维度最新证据进一步揭示其治疗潜力。1、减重之外的直接肝脏影响一项多中心、随机、双盲、剂量探索Ⅱ期临床试验，探讨了Survodutide在MASH伴肝纤维化（F1-F3期）患者中的有效性和安全性。针对其中170例F2/F3期肝纤维化患者的中介分析显示，Survodutide对肝脏终点的治疗效应分为体重依赖与非依赖两部分[7]。对于PRO-C3、ELF评分、AST、ALT等炎症和纤维化相关指标，Survodutide不依赖于体重减轻，主要通过GCG效应实现对肝脏直接获益；而MASH消退/缓解、磁共振质子密度脂肪分数（MRI-PDFF）、受控衰减参数（CAP）等指标的改善则部分依赖体重减轻（图2）。这一结果提示，Survodutide可通过GCGR直接作用于肝脏，而非仅通过减重间接改善。图2. 由体重减轻介导的各项指标百分比2、无创生物标志物的持续改善Ⅱ期试验的一项纵向分析显示，Survodutide治疗48周可持续改善多类无创生物标志物[8]。肝纤维化相关标志物中，ELF评分较基线水平的绝对降幅（0.57-0.61）显著高于安慰剂组（0.05，均P＜0.0001；图3），其组分透明质酸、Ⅲ型前胶原前肽（PⅢNP）、金属基质蛋白酶组织抑制因子1（TIMP-1）均显著降低（P＜0.01；表1）。图3. ELF评分自基线起随时间的估计绝对变化表1. 第4、28和48周时，透明质酸、PⅢNP和TIMP-1水平的估计几何均数Survodutide组的PRO-C3相对降幅为0.71-0.74（安慰剂组1.01，P＜0.0001），FIB-4指数相对降幅为0.80-0.85（安慰剂组1.04，P＜0.001），AST与血小板比率指数（APRI）相对降幅为0.49-0.53（安慰剂组0.94，P＜0.0001）。肝细胞存活相关的CK18-M30、CK18-M65相对降幅分别为0.25-0.34、0.3-0.4（安慰剂组分别为0.78、0.9，P＜0.0001），提示肝细胞损伤减少。3、无创检测对肝活检结局的预测价值一项纳入95例Survodutide治疗的F2/F3期患者的探索性分析显示，部分非侵入性检测（NIT）变化可有效预测肝活检结局[9]。对于“MASH消退且纤维化无恶化”，MRI-PDFF相对变化、ELF评分绝对变化、FAST评分相对变化为主要预测因子（表2），全数据集AUC为0.854（95%CI：0.777-0.932，P＜0.0001；图4）。表2. NIT对预测“MASH消退且纤维化未恶化”结局的相对重要性图4. 预测MASH消退且纤维化未恶化的ROC曲线对于“纤维化改善且MASH无恶化”，ELF评分绝对变化、ALT相对变化、PRO-C3相对变化、MRI-PDFF相对变化、FAST评分相对变化为关键预测因子（表3），全数据集AUC为0.811（95%CI：0.727-0.895，P＜0.0001；图5）。这表明，NIT应在临床试验及临床实践中发挥重要的作用。表3. NIT对预测“纤维化改善且MASH未恶化”结局的相对重要性图5. 预测纤维化改善且MASH未恶化的ROC曲线4、获益机制探究在模拟健康人和MASH患者肝脏表型的肝球体模型中，观察到Survodutide可升高环磷酸腺苷（cAMP）水平，而司美格鲁肽、替尔泊肽未升高cAMP[10]。同时，Survodutide在MAFLD肝球体中升高cAMP水平的绝对增加幅度是瘦体重对照组的3倍[10]。提示其通过GCGR-cAMP通路发挥肝脏保护作用。此外，Survodutide展现出抗脂肪变性与抗纤维化作用[10]。与对照肝球体相比，MASH肝球体甘油三酯含量显著增加9.8倍，PC-1分泌量显著增加10.3倍（P＜0.0001）；Survodutide 0.3μmol/L可使细胞内甘油三酯含量显著降低23.8%（P＜0.05），1μmol/L可使PC-1分泌量降低35.0%。图6. Survodutide对肝球体的浓度-效应关系：a）PC-1分泌量；b）甘油三酯含量[均值±标准误]；c）为多种候选药物（圆点）与Survodutide（方形）PC-1分泌量相较甘油三酯水平百分比的散点图（以MASH溶剂对照进行标准化）；LDH值以氯丙嗪依赖性LDH释放百分比的颜色密度热图呈现写在最后Survodutide的多项最新研究进展在MASH伴肝纤维化治疗领域展现出多重临床价值。研究显示，Survodutide具有独立于体重的直接肝脏效应，其或可对于非肥胖MASH患者也具潜力。Survodutide可持续改善多项无创生物标志物，无创检测指标的变化可有效预测肝活检结局。体外研究也进一步探究了GCGR-cAMP通路的肝脏获益机制，为药物的临床获益提供了理论支持。参考文献：[1] Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. doi:10.1097/HEP.0000000000000520[2] European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. doi:10.1016/j.jhep.2024.04.031[3] Dong X, Li JM, Lu XL, et al. Global burden of adult non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has been steadily increasing over the past decades and is expected to persist in the future. Transl Gastroenterol Hepatol. 2024;9:33. Published 2024 Jun 24. doi:10.21037/tgh-23-118[4] Del Prato S, Gallwitz B, Holst JJ, Meier JJ. The incretin/glucagon system as a target for pharmacotherapy of obesity. Obes Rev. 2022;23(2):e13372. doi:10.1111/obr.13372[5] Sánchez-Garrido MA, Brandt SJ, Clemmensen C, Müller TD, DiMarchi RD, Tschöp MH. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia. 2017;60(10):1851-1861. doi:10.1007/s00125-017-4354-8[6] Zimmermann T, Thomas L, Baader-Pagler T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022;66:101633. doi:10.1016/j.molmet.2022.101633[7] Noureddin M, et al. 胰高血糖素受体/胰高血糖素样肽-1受体双激动剂Survodutide在减重之外对肝脏终点的直接影响：来自II期试验的启示. 中华医学会第二十五次消化系病学术会议(CGC2025).[8] Noureddin M, et al. 新型胰高血糖素受体/胰高血糖素样肽-1受体双激动剂Survodutide对无创生物标志物的持续改善：一项针对代谢相关脂肪性肝炎合并纤维化患者II期试验的纵向分析. 中华医学会第二十五次消化系病学术会议(CGC2025).[9] Noureddin M, et al. 用于预测Survodutide治疗后肝活检结果的非侵入性检测：II期试验探索性分析[EB/OL]. 中华医学会第二十五次消化系病学术会议(CGC2025).[10] Vonschallen P, et al. Survodutide在人肝细胞球模型中通过胰高血糖素组分激活cAMP信号通路并减少脂肪变性和纤维化. 中华医学会第二十五次消化系病学术会议(CGC 2025).SC-CN-18167，有效期至2026.10.28

临床结果

2025-10-29

·铑财

终止定增、业绩双降博瑞医药再上市底气知多少

与其相忘江湖，不如点上方蓝字关注铑财独立稀缺穿透风物长宜放眼量，天助自助者作者：张浩编辑：马可风品：李莉来源：铑财——铑财研究院定增募资也叫定向增发，是上市公司向特定投资者非公开发行股票的一种融资方式，有利企业引入战投优化资本结构，但低价发行或募资用于偿债可能稀释业绩，还易被解读为资金短缺信号‌。眼下，博瑞医药的定增操作正引市场关注。 10月16日，公司公告称，终止2024年度向特定对象发行A股股票事项，并撤回相关申请文件。该计划原拟募不超5亿元，用于补流及偿还银行贷款。公司解释系“综合考虑当前市场环境、公司实际情况及发展规划”，旨在“保护全体股东利益尤其是中小投资者利益”。话虽如此，10月18日博瑞又公告称，在2025年第一次临时股东大会上，《关于公司发行H股股票并在香港联合交易所有限公司主板上市的议案》等议案获得通过。一边终止A股定增、一边筹划港股上市，两项看似矛盾的决策背后，博瑞医药有何战略考量？经营面咋样呢？ 01 股价起落背后终止定增VS赴港上市 LAOCAI 不算多苛求，回顾此次定增，前后筹划近一年半时间。 2024年5月6日，博瑞医药召开董事会及监事会会议，审议通过了《关于2024年度向特定对象发行A股股票预案的议案》等相关议案，随后5月20日股东大会通过。根据方案，此轮定增公司董事长兼总经理、实控人之一的袁建栋将以现金认购全部股票，价格22.36元/股，最高5亿元，用于补充流动资金和偿还贷款，限售期48个月。一年后，即2025年5月8日，公司对发行预案进行修订，7月18日再次修订，8月8日收到上交所出具的受理发行证券申请通知。然而，还没等上交所发审核问询，公司就主动撤回申请、宣布定增终止。值得注意的是，当定增计划波折进行时，公司股价也剧烈波动。2024年5月发行预案公布时，博瑞医药股价约30元，按22.36元的定增价格计实控人独揽定增比较“合算”。然随着“9·24”行情启动，加上创新药概念热炒，博瑞医药股价大幅上涨。进入2025年，从7月11日开始博瑞医药股价短短一月从55元最高涨到120元附近。其中，8月6日最高报122.59元，创上市后新高。随后8月中旬又开始震荡下跌模式，截至10月29日收于54.49元，较最高点跌去超55%，短短三月大起大落好似经历“过山车”。不过以10月29日收盘价计，袁建栋账面浮盈仍超8亿元。且即便经历大缩，29日最新滚动市盈率仍达230.61倍，而同期医药制造业月平均滚动市盈率仅30.82倍。公司也特别提醒广大投资者“注意投资风险，理性决策，审慎投资”。另一厢，虽开启二次上市征途，但截至目前，“其他关于本次发行上市的具体细节尚未确定”，且“本次发行上市能否通过审议、批准、核准和备案程序并最终实施具有重大不确定性”。行业分析师孙业文指出，博瑞医药原计划定增补流和还贷。终止意味着公司短期失去这一重要资金来源，可能会对资金链产生一定压力，尤其偿债和维持日常运营方面。不过，如能成功H股上市，将获得更强大且持久的融资支持，有助加速创新药研发和商业化进程。 02 首次营利双滑传统主业疲软、资金压力几何 LAOCAI 看看业绩基本面，确实该加把劲儿了。 2022-2024年，博瑞医药营收10.17亿元、11.8亿元、12.83亿元，持续增长，然净利却跑出了反差下滑，分别为2.4亿元、2.02亿元、1.89亿元。 2025上半年加速恶化，营收5.37亿元，同比下降18.28%；净利1717.32万元，同比大降83.85%。不仅是2019年上市以来首次中报营利双滑，净利降幅也刷新中报历史。对此，博瑞医药表示，业绩下滑受流感趋势变化及竞争格局变化影响，比如奥司他韦原料药及制剂需求及价格产生下滑，使得抗病毒类产品收入、毛利额均较上年同期大减。此外，在建工程转固带来的计提折旧增加。打深一度看，业绩走弱与核心产品表现乏力分不开。企业官网资料显示，博瑞医药已上市与在研产品管线覆盖代谢、肿瘤、呼吸、免疫抑制、抗病毒真菌等治疗领域，旗下有抗病毒类、抗真菌类、免疫抑制类、其他类产品的原料药几大产品系列。其中，原料药是公司核心产品和传统主业，2024年报显示原料药业务贡献超七成营收。2025上半年占比仍达75.72%，但规模降至4.07亿元，较去年同期减少19.30%。细分产品，受流感趋势变化与市场竞争加剧双重影响，2025上半年抗病毒类原料药收入同比锐减66.18%。其中，奥司他韦系列产品更是面临需求与价格同步下滑压力；曾长期扛起增长大旗的抗真菌类原料药，向来是高毛利代表，却因客户需求波动出现收入下滑。此外，受奥司他韦制剂需求及价格承压的传导影响，公司制剂产品收入同比减少30.57%，仅录得7621.41万元。值得警惕的是，2025上半年，合同负债同比下降11.23%至2882.16万元。众所周知，该指标是企业已收或应收客户对价，但尚未履行向客户转让商品或服务义务的现时责任，往往反映未来订单预期，下滑需警惕市场信心不足，让后续业绩承压。同期，公司经营活动产生现金流量净额同比下滑24.87%，货币资金7.40亿元同比下降22.46%‌。账上现金及现金等价物7.31亿元、同比下降22.9%。另一厢，短期借款同比增加24.42%至1.69亿元，一年内到期非流动负债同比增加25.32%至6.61亿元，短债合计8.3亿元，尚存近1亿元缺口。升降之间，现金流压力自知。“造血”力减弱，就凸显外部“输血”的重要性。2019年11月，博瑞医药登陆科创板，募资净额4.4亿元；2022年1月，按面值发行4.65亿元可转债；2022年11月，又向特定对象发行12464,966股新股，发行价18.18元/股，募资总额2.27亿元；3次合计融资超12亿元。若加上上述未竟的定增以及正在筹划的港股上市，博瑞医药短短6年间融资频率不算低。 03 研发“吞金” 创新药能否撑起新曲线 LAOCAI 受政策红利与市场需求共同推动，近几年不少原料药企业纷纷向创新药转型，比如石药集团‌通过多次战略调整从原料药（青霉素、维生素C等）逐步转型为创新药企，东北制药‌通过子公司鼎成肽源布局细胞治疗领域。这其中，以GLP-1（胰高血糖素样肽 1）为代表的减重赛道因前景较好，受到资本热捧。作为近年来医药领域突破性靶点，GLP-1受体激动剂市场前景与临床价值正呈多维度爆发式增长。据诺和诺德和礼来财报，该领域头部产品美格鲁肽和替尔泊肽2024年全球销售额分别超250亿美元、150亿美元，跻身世界商业价值最高药品之列。博瑞医药的看点也在于此，公司持续聚焦代谢疾病领域，围绕GLP-1类多肽药物展开布局，并探索口服化等新型给药方式，力图在慢性代谢疾病治疗中建立差异化优势。在当家人袁建栋看来，仿制药市场存在局限性，企业需针对“未被满足的临床需求”进行创新，展现创新药研发效率，强调创新药研发应注重“产品迭代”而非数量堆积，通过全球布局增强国际竞争力。具体产品及进展上，核心品种BGM0504注射液作为GLP-1/GIP双重激动剂，具备降糖、减重及治疗非酒精性脂肪性肝炎（NASH）的潜力。据界面新闻，BGM0504注射液国内2型糖尿病和减重两大适应症的Ⅲ期临床均已完成全部入组，处于给药和随访阶段。同时，该注射液减重适应症在美国开展的US bridging临床研究也已完成，并与FDA进行Type B End-of-Phase 2会议，讨论了Ⅲ期临床方案。且由合作伙伴递交申请，印尼三期临床研究工作已正式启动。9月29日博瑞医药向媒体表示，印尼III期已开始给药。此外，博瑞医药还在研口服BGM0504片剂、长效胰淀素（Amylin）类似物BGM1812。据科创板日报，前者已取得FDA临床批准，开展Ⅰ期临床，进展快于国内；代谢线全新品种BGM1812注射液也完成了中美临床双申报，口服版目前处于临床前研发阶段。还新增两个基于BGM0504的复方制剂，分别面向减重、降糖场景。不过虽进展喜人，可截至2025年9月底，博瑞医药还没有上市的GLP-1类产品。这也印证了创新药研发周期长、投入高、风险大的特点，短期内难转化为收入。继而让博瑞医药面临传统核心业务增长乏力、创新药产品又尚在培育、支出增多的尴尬局面。以2025上半年为例，研发投入金额已超2024全年的3.12亿元、达到3.48亿元，同比增长144.07%，占营收比64.83%。投入高度集中于创新药及吸入制剂领域，占比达91.22%。所谓不创新无未来、上述投入有战略蓄力深意，可新药研发仍面临不确定性。虽然减重赛道堪称爆款药物诞生地，可伴随竞品不断入局、需警惕高增红利期的逐渐减弱。比如头部企业诺和诺德，7月末就宣布下调全年销售增速、营业利润增速至少5个百分点，这提示后来者要更加细致地评估行业前景、加快研发脚步及质量。要知道，竞品们都没闲着，除了辉瑞、礼来这样强劲的对手，还有信达生物、恒瑞医药等在争夺市场。药企转型从非易事。对博瑞医药而言，破局的关键在于研发管线兑现能力，比如BGM0504等GLP-1品种临床突破、实现商业化落地。在此之前，公司需平衡研发投入与盈利节奏，协调好短期偿债与长期投入，统筹传统与新兴业务协同发展，避免“过度烧钱”拖累整体业绩。较劲时刻，考验企业的内控治理、合规经营水平。2025年6月28日，博瑞医药公告称，公司及财务总监收到《警示函》。该函显示：2019年11月27日董事会审议通过使用不超3.8亿元闲置募资进行现金管理，期限12个月，但2020年11月26日决议期限届满后未及时赎回产品，直至2020年12月11日才补审议程序，期间未履行信披义务。邹元来作为财务总监因未勤勉尽责被同步警示。拉长维度，2020年3月，博瑞医药公告收到《警示函》。经核查，公司公告中所称“批量生产”实际为药品研发中小试、中试等批次的试验性生产，而非已完成审批并开始正式规模化、商业化生产销售瑞德西韦原料药和制剂。公司所披露的“批量生产”未考虑一般语义的理解，亦未作出专门说明，不能准确描述抗病毒药物研制的进展，信息披露不准确。无独有偶。因董事长袁建栋曾表示，本人亲自试药(BGM0504注射液)，体重从91公斤降到76公斤(减重30斤)，2023年10月17日博瑞医药公告，袁建栋因此收到江苏证监局警示函。 04 四大看点翻盘底气知多少 LAOCAI 凡事皆有两面。挑战隐忧之外，若从产线布局、战略前瞻与转型潜力等角度看，博瑞医药仍值期待。首先，得益多年战略深耕，逐渐形成全产业链协同布局。作为国际性创新药企业，博瑞医药依靠研发驱动，聚焦首仿、难仿、特色原料药、复杂制剂和原创性新药。区别于传统原料药公司，其选择技术壁垒较高、市场刚需药物自研，贯通“起始物料-高难度中间体-特色原料药-制剂”全链条，创新质量及潜在价值不容小觑。整体来看，博瑞医药已形成“原料药+制剂+创新药”全产业链，尤其在代谢疾病领域形成差异化竞争力。2024年报显示，公司原料药业务覆盖40多个国家、并与梯瓦制药等巨头合作，为创新药商业化提供渠道基础。此外，吸入用布地奈德混悬液等高壁垒仿制药的申报进展，有望形成“仿创结合”的现金流互补模式。就在10月28日，博瑞医药公告称，子公司产品地诺孕素片拟中标全国药品集中采购。该产品适应症为子宫内膜异位症，规格为2mg，拟中标价24.7元/盒，首年约定采购量基数为130.2813万片，主供省份为河北、四川、陕西、海南、宁夏，采购周期至2028年12月31日。2025年1-9月其产生销售收入173.51万元。本次拟中标有利产品快速打开国内销售市场，提高市场占有率，促进公司制剂业务发展。其次，持续大力度研发投入为长期竞争力、业绩反转积势蓄能。以2024年为例，博瑞医药重点在代谢疾病领域开发具有全球自主知识产权的创新药物，在呼吸吸入为主的药械组合领域构建具有国际竞争力的产品线，研发投入3.12亿元、同比增长25.42%、占营收24.31%。报告期内，公司新提交国内专利申请41件，新获得国内专利授权28件；新提交国外专利申请12件，新获得国外专利授权5件；截至2024年12月末，累计申请专利506件，其中发明专利448件；拥有有效专利共269件，其中发明专利224件，布局美国、日本、加拿大、欧洲、韩国等多个国家和地区。再者，国际化布局具备一定先发优势。目前，公司药品生产体系通过了美国、欧盟、日本和韩国官方GMP认证，产品覆盖欧盟、美国、日韩等国家或地区，比如BGM0504获美国FDA临床试验批准、瞄准全球肥胖与糖尿病市场。‌ 最后，融资环境向好提供了外部条件。当前港股涌现医药企业上市潮。5月23日恒瑞医药港交所上市，成为近几年港股医药板块最大IPO；8月7日东阳光药登陆港交所，成为香港市场首例H股吸收合并私有化加介绍上市案例；A股老牌药企贝达药业也拟港交所主板上市。Wind数据显示，今年前三季，港交所完成68宗IPO项目，较去年同期增加23家，增幅51.11%；募资总额1823.96亿港元，已远超2024全年的881.47亿港元。这与政策推动和制度优化分不开。港交所2018年推出的18A章允许未盈利生物科技公司上市，2025年进一步优化“科企专线”，提供保密递表、预审指导等专项服务，吸引创新药企密集递表。在此背景下，一旦如愿“A+H”上市，将极大改善博瑞医药资金面，为其上述蓄力战略留出更多腾挪空间。‌ 实控人带头表达的回购意愿也向外界传递了发展信心。9月25日晚，博瑞医药公告称，袁建栋提议公司使用自有资金以集中竞价交易方式进行股份回购。本次回购金额不低于1000万元（含），不超2000万元（含）。显然，博瑞医药也握有一定的反转底牌、潜在价值筹码。可以说当前正处在一个关键节点。危与机往往并存，克服了危便是机。虽然博瑞医药此次定增夭折，又面临业绩压力，但依托全产业链技术优势和国际化布局，其在代谢疾病领域已构筑了技术壁垒。能否以二次上市为契机，协调新老业务发展、平衡短期与长期利益、强化核心技术壁垒、增强变现造血力、提振业绩，短期关乎IPO成败、长期影响企业可持续发展，就看管理层的智慧与魄力了。风物长宜放眼量，天助自助者。本文为铑财原创如需转载请留言本账号系新浪财经／一点资讯／凤凰新闻／网易财经／搜狐财经／腾讯财经／今日头条／蓝鲸财经／百度百家／新浪微博／天天快报／中金在线／东方财富／雪球等25家媒体入驻账号稿件内容微信：Hualidkx 商务合作微信：Yuqee66 更多好文，请长按下方二维码关注铑财

IPO

100 项与替尔泊肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11360	替尔泊肽	-	DB15171

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肥胖通气不足综合征	中国	礼来苏州制药有限公司	2025-06-30
阻塞性睡眠呼吸暂停综合征	美国	Eli Lilly & Co.	2024-12-20
肥胖	美国	Eli Lilly & Co.	2023-11-08
超重	美国	Eli Lilly & Co.	2023-11-08
体重增加	澳大利亚	Eli Lilly Australia Pty Ltd.	2022-12-23
2型糖尿病	美国	Eli Lilly & Co.	2022-05-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
射血分数保留型心力衰竭	申请上市	中国	Eli Lilly & Co.	2024-11-22
溃疡性结肠炎	临床3期	美国	Eli Lilly & Co.	2025-06-26
溃疡性结肠炎	临床3期	奥地利	Eli Lilly & Co.	2025-06-26
溃疡性结肠炎	临床3期	比利时	Eli Lilly & Co.	2025-06-26
溃疡性结肠炎	临床3期	巴西	Eli Lilly & Co.	2025-06-26
溃疡性结肠炎	临床3期	保加利亚	Eli Lilly & Co.	2025-06-26
溃疡性结肠炎	临床3期	加拿大	Eli Lilly & Co.	2025-06-26
溃疡性结肠炎	临床3期	捷克	Eli Lilly & Co.	2025-06-26
溃疡性结肠炎	临床3期	丹麦	Eli Lilly & Co.	2025-06-26
溃疡性结肠炎	临床3期	法国	Eli Lilly & Co.	2025-06-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05963022 (CTgov)	临床3期	2型糖尿病	206	Tirzepatide (10 mg Tirzepatide)	衊齋淵醖獵壓淵範觸繭(積齋製鏇壓顧繭襯獵壓) = 顧獵蓋齋網廠積餘窪遞獵蓋顧觸遞鹽膚艱範夢 (網艱繭簾壓遞鏇衊糧醖, 0.131) 更多	-	2025-10-21
				Tirzepatide (15 mg Tirzepatide)	衊齋淵醖獵壓淵範觸繭(積齋製鏇壓顧繭襯獵壓) = 範範鑰願蓋夢淵鹹範獵獵蓋顧觸遞鹽膚艱範夢 (網艱繭簾壓遞鏇衊糧醖, 0.124) 更多
NCT06914141 \| NCT06914154 \| NCT06914102 (Pubmed \| JAMA)	N/A	射血分数保留型心力衰竭	97,790	Semaglutide	鏇鬱範獵淵選壓築齋醖(鹽襯廠糧壓範範築鬱選): HR = 0.58 (95.0% CI, 0.51 ~ 0.65) 更多	积极	2025-10-14
				Tirzepatide
NCT05260021 (SURPASS-PEDS, PRNewswire) 人工标引	临床3期	2型糖尿病	99	Mounjaro 5 mg	夢獵壓顧觸衊構壓鏇憲(壓網製鬱範遞網築鹹願) = 獵醖淵糧壓願夢構觸醖憲鑰蓋糧夢蓋繭積獵衊 (願遞廠襯顧夢蓋願淵淵 ) 达到更多	积极	2025-09-17
				Mounjaro 10 mg	夢獵壓顧觸衊構壓鏇憲(壓網製鬱範遞網築鹹願) = 鹽夢廠鬱簾窪艱繭艱糧憲鑰蓋糧夢蓋繭積獵衊 (願遞廠襯顧夢蓋願淵淵 ) 达到更多
NCT05822830 (SURMOUNT-5, NEWS) 人工标引	临床3期	肥胖	-	Tirzepatide	齋築網鬱簾壓積衊網餘(顧膚蓋衊廠願網築網獵) = 顧顧製積醖餘製鏇鑰網網憲壓鏇艱壓積鏇廠糧 (壓壓夢齋衊夢壓顧願糧 ) 更多	积极	2025-09-01
				Semaglutide	齋築網鬱簾壓積衊網餘(顧膚蓋衊廠願網築網獵) = 獵鏇襯鬱選餘獵積餘壓網憲壓鏇艱壓積鏇廠糧 (壓壓夢齋衊夢壓顧願糧 ) 更多
NCT04311411 (Pubmed \| Nat Med)	临床1期	超重 \| 肥胖	114	Tirzepatide	構蓋醖襯鹽獵遞選艱淵(鹽淵糧鹹鹽構範願簾膚) = 鬱築選壓夢鑰餘齋窪蓋網鹽範網獵窪齋衊淵淵 (繭選餘壓醖鹽醖餘選顧, -648.1 ~ -401.0)	积极	2025-09-01
				Placebo	-
NCT06914141 \| NCT06914154 \| NCT06914102 (JAMA) 人工标引	N/A	射血分数保留型心力衰竭	97,790	Semaglutide	艱顧鹹蓋鹽衊顧衊築製(鹽醖壓鹹壓獵鏇襯網壓): HR = 0.58 (95.0% CI, 0.51 ~ 0.65) 更多	积极	2025-08-31
				sitagliptin
NCT05822830 (SURMOUNT-5, Pubmed \| Eur Heart J Open)	临床3期	肥胖	296	Tirzepatide	襯餘膚獵積選繭遞窪範(淵夢觸鏇衊觸憲願繭鏇) = 窪壓構築網廠鹹餘齋鑰積顧膚衊願獵顧壓襯構 (築夢艱夢餘淵膚艱鏇獵 )	积极	2025-08-29
				Semaglutide	襯餘膚獵積選繭遞窪範(淵夢觸鏇衊觸憲願繭鏇) = 觸膚築廠選餘網齋襯醖積顧膚衊願獵顧壓襯構 (築夢艱夢餘淵膚艱鏇獵 )
NCT05696847 (CTgov)	临床1期	肥胖	28	Placebo (Cohort 1: Placebo (BW >=50 kg))	壓鬱鬱鑰襯齋簾齋夢糧 = 夢餘願淵鑰鏇衊襯醖淵廠顧顧艱觸壓衊簾願範 (鹹壓鹹鹽鏇膚餘齋艱壓, 淵鹽遞廠構積糧繭簾鹹 ~ 願蓋鹹鹽築積積製獵壓) 更多	-	2025-08-26
				Tirzepatide (Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg))	壓鬱鬱鑰襯齋簾齋夢糧 = 廠選鑰膚膚遞範願膚選廠顧顧艱觸壓衊簾願範 (鹹壓鹹鹽鏇膚餘齋艱壓, 網網簾觸築觸鏇憲鹹製 ~ 製鬱廠鬱鬱鹽餘鏇窪窪) 更多
NCT04847557 (SUMMIT, CTgov)	临床3期	射血分数保留型心力衰竭 \| 肥胖	731	Placebo	廠積淵選製窪壓積鬱糧(廠繭艱艱蓋蓋築壓鹽範) = 窪構壓憲廠鏇壓齋衊膚鏇糧選遞膚淵憲選願夢 (顧醖壓鑰艱鹽襯齋齋鑰, 1.25) 更多	-	2025-08-20
NCT05691712 (SURPASS-CN-INS, CTgov)	临床3期	2型糖尿病	257	Tirzepatide (10 mg Tirzepatide)	積願繭齋築鹹顧構觸觸(積鑰艱醖鏇遞範餘範夢) = 鬱築衊鬱鏇鑰製築餘窪窪餘窪構鏇鹽鹹鬱膚鑰 (襯網構網築鹽蓋淵蓋鑰, 1.367) 更多	-	2025-08-08
				Tirzepatide (15 mg Tirzepatide)	積願繭齋築鹹顧構觸觸(積鑰艱醖鏇遞範餘範夢) = 齋壓顧淵遞夢選蓋觸糧窪餘窪構鏇鹽鹹鬱膚鑰 (襯網構網築鹽蓋淵蓋鑰, 1.386) 更多